Bluejay Therapeutics, has revealed new findings from its Phase 2 trial of BJT-778.

Zanubrutinib is a small molecule drug that targets the BTK enzyme and is approved for use in various therapeutic areas including neoplasms.

Acepodia has received FDA approval for the Investigational New Drug Application of ACE1831 to treat IgG4-related disease.

Retifanlimab, a groundbreaking therapeutic agent, is a fully humanized monoclonal antibody developed by Incyte Corporation.

Syndax has received FDA approval for Revuforj® (revumenib), marking it as the first menin inhibitor for treating adults and children with relapsed or refractory acute leukemia featuring a KMT2A translocation.

The drug VVD-130037 is a small molecule drug developed to target the KEAP1 x Nrf2 pathways in the treatment of neoplasms.

InnoCare reports the initial dosing of a participant in China's Phase III trial of the TYK2 inhibitor ICP-332 for treating atopic dermatitis.

Inotuzumab Ozogamicin, also known as Besponsa, is an antibody-drug conjugate (ADC) developed by Pfizer.

AC Immune Announces Favorable Preliminary Findings from Phase 2 Study of ACI-7104.056 Active Immunotherapy for Early Parkinson’s Disease.

Risperidone is a small molecule drug that acts on the 5-HT2A and D2 receptors.

Blenrep demonstrates improved overall survival in the DREAMM-7 phase III trial for relapsed/refractory multiple myeloma.

Antisense oligonucleotide (ASO) drugs represent a significant branch of the small nucleic acid therapeutic field, functioning as molecules that regulate gene expression through specific binding to mRNA.